REGULATORY

Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing

October 24, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s key reimbursement policy panel on October 23 gave a cold shoulder to the pharma industry’s call for giving more flexibility to the selection of comparator products in new drug pricing - a proposal towards the next pricing reform in…

To read the full story

Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019

REGULATORY

Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…